Biotech and Pharma

Tesla rises after President Donald Trump says he struck a deal to set 15% tariffs on goods from the European Union, including automobiles.

The health sciences company posts better-than-expected adjusted earnings and revenue but trims its guidance.

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.

The outlook for shares is bleak after another batch of worrying headlines.

Net income at Tesla falls 16% in the second quarter, while Alphabet says quarterly cloud revenue jumped 32%.

European pharmaceutical stocks have swooned while the broader market has climbed higher. As a result, stocks in the sector are looking like a buying opportunity.

Viking Therapeutics is expected to disclose data on its oral weight-loss drug VK2735.

The market is headed for a seasonally difficult period in late summer, but there is no catalyst for a longer-lasting decline.

There are about $10.5 billion of biotech convertibles outstanding, roughly 3% of the $305 billion market, according to BofA Securities. 

As part of the deal with Indonesia, the U.S. will have access to its critical minerals.

General Motors tops earnings estimates but the stock falls, and Lockheed Martin stock declines after the defense contractor’s earnings included charges of $1.7 billion that took Wall Street by surprise.

Replimune says the FDA issued a letter highlighting concerns with the biotech’s trial design.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

If gains hold, that’d be the stock's largest single-day increase on record.

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Verizon tops earnings expectations and raises 2025 guidance.

A Goldman ranking of S&P 500 sectors by price/earnings ratios reveals opportunities in healthcare stocks.

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, a BMO survey suggests.

Second-quarter profit jumps 46% at Netflix, while a report says Union Pacific is in early-stage talks to buy smaller railroad rival Norfolk Southern.

The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after two teenage boys receiving the treatment died earlier this year.

The pharmaceutical company says its eye inflammation treatment didn’t meet its target.

Lucid soars after announcing a self-driving partnership with Uber Technologies and Nuro, Taiwan Semiconductor Manufacturing reports a record profit in the second quarter, and PepsiCo’s adjusted earnings top forecasts.

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene therapy Elevidys.

The company, which has spent billions over the past decade to acquire dozens of smaller companies, has a long track record of strong growth.

Shares of the sleep-apnea treatment maker have gained 32% since Barron’s recommended them.

ASML falls sharply after issuing a growth warning, while Goldman Sachs, Morgan Stanley, and Bank of America post better-than-expected quarterly earnings.